Treatment of Opioid-Use Disorders
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
T his article provides an overview of the current treatment of opioid-related conditions, including treatments provided by general practitioners and by specialists in substance-use disorders.The recent dramatic increase in misuse of prescription analgesics, the easy accessibility of opioids such as heroin on the streets, and the epidemic of opioid overdoses underscore how important it is for physicians to understand more about these drugs and to be able to tell patients about available treatments for substance-use disorders.Opioids include most prescription analgesics as well as products of the poppy plant (e.g., opium, morphine, and codeine).1 Although opioids usually are prescribed to control pain, diminish cough, or relieve diarrhea, they also produce feelings of euphoria, tranquility, and sedation that may lead the patient to continue to take these drugs despite the development of serious related problems.These problems include the need to escalate doses in order to achieve these desired effects; such levels of opioids can overwhelm respiratory drive and lead to death.1,2 Opioid-use disorders are seen in persons from all educational and socioeconomic backgrounds.Recognition of such disorders has contributed to efforts to change physicians' prescribing practices and to train first responders regarding the parenteral administration of naloxone (Narcan or Evzio), a mu-opioid receptor antagonist. 2 In the United States, an estimated 400,000 persons have used heroin in the past month and 4 million have reported nonmedical use of prescription pain relievers.[3][4][5] By some estimates, almost 17,000 deaths per year are related to opioids; drug poisoning is one of the leading causes of accidental death in the United States.Approximately 3 million persons in the United States and almost 16 million worldwide have a current or past opioid-use disorder.6 The global burden of disease from opioid-related conditions approaches 11 million life-years lost from health problems, disabilities, and early death.7 In the 2013 Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association (Table 1), an opioid-use disorder is defined as the repeated occurrence within a 12-month period of 2 or more of 11 problems, including withdrawal, giving up important life events in order to use opioids, and excessive time spent using opioids.A cluster of 6 or more items indicates a severe con dition.4,8 The clinical course of opioid-use disorders involves periods of exacerbation and remission, but the underlying vulnerability never disappears. 1 This pattern is similar to that of other chronic relapsing conditions (e.g., diabetes and hypertension) in which perfect control of symptoms is difficult and patient adherence to treatment is often incomplete.Although persons with opioid problems are likely to have extended periods of abstinence from opioids and often do well, 9 the risk of early death, primarily from an accidental overdose, trauma, suicide, or an infectious disease (e.g., human immunodeficiency virus [HIV] infection), is increased by a factor of 20. [10][11][12][13][14][15] Legal problems are especially likely in persons with criminal records and high impulsivity.13 The risk of adverse outcomes decreases markedly with abstinence from opioids.9,16
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A key component of OUD is the development of long-lasting drug craving (3–5), whether in the context of prescribed opioids, such as for analgesic purposes, or illicitly acquired heroin.”
From Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice (2019) · cites this paper as [5]
In the citing paper
“Inhibition of craving has long been a goal of OUD treatment (5).”
From Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice (2019) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,274
A Meta-Analytic Review of Psychosocial Interventions for Substance Use Disorders
Dutra, L., Stathopoulou, G., Basden, S. L., Leyro, T. M., Powers, M. B., & Otto, M. W. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111851 · Cited by 1,287
Trends in Opioid Analgesic Abuse and Mortality in the United States
Dart, R. C., Surratt, H. L., Cicero, T. J., Parrino, M. W., Severtson, S. G., Bucher-Bartelson, B., & Green, J. L. (2015) · New England Journal of Medicine · doi:10.1056/nejmsa1406143 · Cited by 1,137
The Clinical Opiate Withdrawal Scale (COWS)
Wesson, D. R., & Ling, W. (2003) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2003.10400007 · Cited by 1,120
D’Onofrio, G., O’Connor, P. G., Pantalon, M. V., Chawarski, M. C., Busch, S. H., Owens, P. H., Bernstein, S. L., & Fiellin, D. A. (2015) · JAMA · doi:10.1001/jama.2015.3474 · Cited by 910
Schuckit, M. A. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60009-x · Cited by 712
VASILAKI, E. I., HOSIER, S. G., & COX, W. M. (2006) · Alcohol and Alcoholism · doi:10.1093/alcalc/agl016 · Cited by 581
A Systematic Review of Community Opioid Overdose Prevention and Naloxone Distribution Programs
Clark, A. K., Wilder, C. M., & Winstanley, E. L. (2014) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000034 · Cited by 488
Hser, Y., Saxon, A. J., Huang, D., Hasson, A., Thomas, C., Hillhouse, M., Jacobs, P., Teruya, C., McLaughlin, P., Wiest, K., et al. (2014) · Addiction · doi:10.1111/add.12333 · Cited by 455
Methadone maintenance at different dosages for opioid dependence
Faggiano, F., Vigna-Taglianti, F., Versino, E., & Lemma, P. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002208 · Cited by 406
QTc Interval Screening in Methadone Treatment
Krantz, M. J., Martin, J., Stimmel, B., Mehta, D., & Haigney, M. C. P. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-6-200903170-00103 · Cited by 337
Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta‐analytical review
Johansson, B. A., Berglund, M., & Lindgren, A. (2006) · Addiction · doi:10.1111/j.1360-0443.2006.01369.x · Cited by 305
Oral substitution treatment of injecting opioid users for prevention of HIV infection
Gowing, L., Farrell, M. F., Bornemann, R., Sullivan, L. E., & Ali, R. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004145.pub4 · Cited by 296
Alpha2-adrenergic agonists for the management of opioid withdrawal
Gowing, L., Farrell, M., Ali, R., & White, J. M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002024.pub5 · Cited by 271
Prescription Opioid Misuse, Abuse, and Treatment in the United States: An Update
Brady, K. T., McCauley, J. L., & Back, S. E. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15020262 · Cited by 249
Degenhardt, L., Larney, S., Kimber, J., Gisev, N., Farrell, M., Dobbins, T., Weatherburn, D. J., Gibson, A., Mattick, R., Butler, T., et al. (2014) · Addiction · doi:10.1111/add.12536 · Cited by 223
Methadone at tapered doses for the management of opioid withdrawal
Amato, L., Davoli, M., Minozzi, S., Ferroni, E., Ali, R., & Ferri, M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003409.pub4 · Cited by 222
Comparing overdose mortality associated with methadone and buprenorphine treatment
Bell, J. R., Butler, B., Lawrance, A., Batey, R., & Salmelainen, P. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.03.020 · Cited by 182
Discontinuation of Buprenorphine Maintenance Therapy: Perspectives and Outcomes
Bentzley, B. S., Barth, K. S., Back, S. E., & Book, S. W. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2014.12.011 · Cited by 176
Krupitsky, E. M., Zvartau, E. E., Blokhina, E. A., Verbitskaya, E. V., Wahlgren, V., Tsoy-Podosenin, M., Bushara, N., Burakov, A. M., Masalov, D. V., Romanova, T. N., et al. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2012.1a · Cited by 156
Pierce, M., Bird, S., Hickman, M., Marsden, J., Dunn, G., Jones, A., & Millar, T. (2015) · Addiction · doi:10.1111/add.13193 · Cited by 155
The Therapeutic Potential of κ-Opioids for Treatment of Pain and Addiction
Chavkin, C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.137 · Cited by 136
Evans, E., Li, L., Min, J. E., Huang, D. Y. C., Urada, D. I., Liu, L., Hser, Y., & Nosyk, B. (2015) · Addiction · doi:10.1111/add.12863 · Cited by 131
Opioid Detoxification and Naltrexone Induction Strategies: Recommendations for Clinical Practice
Sigmon, S. C., Bisaga, A. M., Nunes, E. V., O’Connor, P. G., Kosten, T. R., & WOODY, G. E. (2012) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2011.653426 · Cited by 130
Teesson, M., Marel, C., Darke, S. G., Ross, J. E., Slade, T. N., Burns, L., Lynskey, M. T., Memedovic, S., White, J., & Mills, K. L. (2015) · Addiction · doi:10.1111/add.12860 · Cited by 127
Potter, J., Marino, E., Hillhouse, M. P., Nielsen, S., Wiest, K., Canamar, C. P., Martin, J. A., Ang, A., Baker, R., Saxon, A., et al. (2013) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.2013.74.605 · Cited by 121
Lee, J. D., McDonald, R. D., Grossman, E., McNeely, J., LASKA, E. M., Rotrosen, J., & Gourevitch, M. N. (2015) · Addiction · doi:10.1111/add.12894 · Cited by 117
Withdrawal From Methadone Maintenance: Rate of Withdrawal and Expectation
Senay, E. C. (1977) · Archives of General Psychiatry · doi:10.1001/archpsyc.1977.01770150119014 · Cited by 117
Humphreys, K., Blodgett, J. C., & Wagner, T. H. (2014) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12557 · Cited by 116
Pinto, H., Maskrey, V., Swift, L., Rumball, D., Wagle, A. C., & Holland, R. (2010) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2010.07.009 · Cited by 114
Kowalczyk, W. J., Phillips, K. A., Jobes, M. L., Kennedy, A. P., Ghitza, U. E., Agage, D. A., Schmittner, J. P., Epstein, D. H., & Preston, K. L. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14081014 · Cited by 101
Sigmon, S. C., Dunn, K. E., Saulsgiver, K. A., Patrick, M. E., Badger, G. J., Heil, S. H., Brooklyn, J. R., & Higgins, S. T. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.2216 · Cited by 95
Buprenorphine: New Tricks With an Old Molecule for Pain Management
Heit, H. A., & Gourlay, D. L. (2008) · Clinical Journal of Pain · doi:10.1097/ajp.0b013e31815ca2b4 · Cited by 88
Degenhardt, L. J., Whiteford, H., & Hall, W. (2013) · Drug and Alcohol Review · doi:10.1111/dar.12088 · Cited by 87
Abuse and diversion of buprenorphine sublingual tablets and film
Lavonas, E. J., Severtson, S. G., Martinez, E. M., Bucher‐Bartelson, B., Lait, M. L., Green, J. L., Murrelle, L., Cicero, T. J., Kurtz, S. P., Rosenblum, A., et al. (2014) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2014.02.003 · Cited by 86
Cousins, G., Boland, F., Courtney, B., Barry, J., Lyons, S., & Fahey, T. P. (2015) · Addiction · doi:10.1111/add.13087 · Cited by 79
Predictors of Opioid-Related Death During Methadone Therapy.
Leece, P., Cavacuiti, C., Macdonald, E., Gomes, T., Kahan, M., Srivastava, A., Steele, L., Luo, J., Mamdani, M., & Juurlink, D. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2015.04.008 · Cited by 79
Evidence-based treatment for opioid disorders: A 23-year national study of methadone dose levels
D’Aunno, T. A., Pollack, H. A., Frimpong, J. A., & Wutchiett, D. M. (2014) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2014.06.001 · Cited by 71
Methods of Detoxification and Their Role in Treating Patients With Opioid Dependence
O’Connor, P. G. (2005) · JAMA · doi:10.1001/jama.294.8.961 · Cited by 69
Dosage Patterns in Methadone Treatment: Results from a National Survey, 1988–2005
Pollack, H. A., & D’Aunno, T. A. (2008) · Health Services Research · doi:10.1111/j.1475-6773.2008.00870.x · Cited by 68
Johnson, B., & Richert, T. (2014) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2014.10.003 · Cited by 67
Narrative Review: Buprenorphine for Opioid-Dependent Patients in Office Practice
Sullivan, L. E., & Fiellin, D. A. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-9-200805060-00006 · Cited by 62
Nielsen, S., Hillhouse, M. P., Mooney, L. J., Ang, A., & Ling, W. W. (2014) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2014.06.006 · Cited by 55
New developments in the management of opioid dependence: focus on sublingual buprenorphine–naloxone
Soyka, M. (2015) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s45585 · Cited by 55
Friedmann, P. D., & Schwartz, R. P. (2012) · Addiction Science & Clinical Practice · doi:10.1186/1940-0640-7-10 · Cited by 52
Nosyk, B., Li, L., Evans, E., Urada, D. I., Huang, D. Y. C., Wood, E., Rawson, R. A., & Hser, Y. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.07.020 · Cited by 47
Huang, C. L.-C., & Lee, C. W. (2012) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2012.08.003 · Cited by 45
Lintzeris, N., Leung, S. Y., Dunlop, A. J., Larance, B., White, N. E., Rivas, G., Holland, R. M., Degenhardt, L. J., Muhleisen, P., Hurley, M., et al. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.12.009 · Cited by 45
Heroin anticraving medications: a systematic review
Fareed, A., Vayalapalli, S., Casarella, J., Amar, R., & Drexler, K. (2010) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2010.505991 · Cited by 41
Mitchell, M. C., Memisoglu, A., & Silverman, B. L. (2012) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.2012.73.991 · Cited by 41
Risk factors for craving and relapse in heroin users treated with oral or implant naltrexone
Hulse, G. K., Ngo, H. T. T., & Tait, R. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.04.003 · Cited by 37
Wright, N. M. J., Sheard, L., Adams, C. E., Rushforth, B., Harrison, W. J., Bound, N., Hart, R., & Tompkins, C. N. E. (2011) · British Journal of General Practice · doi:10.3399/bjgp11x613106 · Cited by 33
Excess mortality among opioid-using patients treated with oral naltrexone in Australia.
Degenhardt, L., Larney, S., Kimber, J., Farrell, M., & Hall, W. (2015) · Drug and Alcohol Review · doi:10.1111/dar.12205 · Cited by 32
Lapham, S. C., & McMillan, G. P. (2010) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e3181eb3b89 · Cited by 28
Launonen, E., Alho, H., Kotovirta, E., Wallace, I., & Simojoki, K. (2015) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2015.03.007 · Cited by 27
Darke, S. G., Marel, C., Slade, T. N., Ross, J. E., Mills, K. L., & Teesson, M. (2015) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.2015.76.909 · Cited by 16
Park, T. W., Cheng, D. M., Lloyd-Travaglini, C. A., Bernstein, J., Palfai, T. P., & Saitz, R. (2015) · Addiction · doi:10.1111/add.13020 · Cited by 10
Whiteside, G. T., & Kyle, D. J. (2013) · ACS symposium series · doi:10.1021/bk-2013-1131.ch016 · Cited by 10
Nosyk, B., Li, L., Evans, E., Urada, D. I., Huang, D. Y. C., Wood, E., Rawson, R. A., & Hser, Y. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.10.018 · Cited by 5
Research works printed but not linked: 8
- O’Brien CP. Drug addiction. In: Brunton L, Chabner B, Knollman B, eds. Goodman & Gilman’s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011:649-666.
- 2012, MMWR Morb Mortal Wkly Rep, 61, 133
- Gowing L, 2014, Cochrane Database Syst Rev, 3, CD002024
- Yaksh TL, Wallace MS. Opioids, analgesia, and pain management. In: Brunton L, Chabner B, Knollman B, eds. Goodman & Gilman’s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011:481-525.
- Amato L, 2013, Cochrane Database Syst Rev, 2, CD003409
- Faggiano F, 2003, Cochrane Database Syst Rev, 3, CD002208
- Gowing L, 2011, Cochrane Database Syst Rev, 8, CD004145
- Mattick RP, 2008, Cochrane Database Syst Rev, 2, CD002207
Cited by
Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy
(2017) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002235 · Cited by 669
Opioid receptors: drivers to addiction?
Darcq, E., & Kieffer, B. L. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0028-x · Cited by 352
Macroeconomic conditions and opioid abuse
Hollingsworth, A., Ruhm, C. J., & Simon, K. (2017) · Journal of Health Economics · doi:10.1016/j.jhealeco.2017.07.009 · Cited by 312
Winkelman, T. N. A., Chang, V. W., & Binswanger, I. A. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.0558 · Cited by 301
Why aren't physicians prescribing more buprenorphine?
Huhn, A. S., & Dunn, K. E. (2017) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2017.04.005 · Cited by 291
Metadata
- Authors
- Schuckit, M. A.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Schuckit, Marc A.
- ORCID
- Schuckit, Marc A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-07-28
- Volume
- 375
- Issue
- 4
- Pages
- 357-368
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2496974376
- Cited by
- 540
- References
- 60
- Citations by year
- 2026: 19 · 2025: 32 · 2024: 34 · 2023: 40 · 2022: 43 · 2021: 71 · 2020: 77 · 2019: 102 · 2018: 70 · 2017: 46 · 2016: 5
- FWCI
- 10.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- opioid use disorder, opioid use disorder treatment, prescription opioid misuse, heroin, opioid overdose, naloxone, opioid antagonists, opioid agonists, buprenorphine, methadone maintenance treatment, naltrexone, sublingual buprenorphine, general practitioners, opioid prescribing, opioid epidemic, opioid-related deaths
- MeSH terms
- Adrenergic alpha-Agonists, Buprenorphine, Humans, Methadone, Opioid-Related Disorders, Substance Withdrawal Syndrome, Opiate Substitution Treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.